The work of consumer outreach and enrollment is never done, as Jennifer Sullivan, director of the Best Practices Institute at Enroll America, said that it’s important to partner with community leaders to continue engaging consumers well into the future.
The work of consumer outreach and enrollment is never done, as Jennifer Sullivan, director of the Best Practices Institute at Enroll America, said that it’s important to partner with community leaders to continue engaging consumers well into the future.
Transcript (slightly modified)
What are the main goals for Enroll America’s plan for outreach and enrollment?
So first and foremost, we will continue our cores, our bread and butter work of the Get Covered America Campaign, which is getting the word out to consumers, reaching as many individual consumers as possible in their communities to make sure they know what’s available to them.
But building on that, we want to connect to them to in-person help in their communities. We want to make it easier for those in-person assisters to reach out and to connect with consumers so that they can complete the enrollment process.
We also want to make sure that we are training, coaching and empowering local community leaders to carry this effort forward in the future. The work of outreach and enrollment will never be done, it’s something that needs to happen every year and we are working really hard to position our partners to continue this work well into the future.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More